US 12,270,078 B2
Methods for diagnosing and treating eosinophilic gastritis
Marc E. Rothenberg, Cincinnati, OH (US); and Tetsuo Shoda, Cincinnati, OH (US)
Assigned to Children's Hospital Medical Center, Cincinnati, OH (US)
Filed by CHILDREN'S HOSPITAL MEDICAL CENTER, Cincinnati, OH (US)
Filed on Feb. 25, 2020, as Appl. No. 16/800,390.
Claims priority of provisional application 62/813,838, filed on Mar. 5, 2019.
Claims priority of provisional application 62/810,093, filed on Feb. 25, 2019.
Prior Publication US 2020/0271668 A1, Aug. 27, 2020
Int. Cl. C12Q 1/68 (2018.01); C12Q 1/6883 (2018.01)
CPC C12Q 1/6883 (2013.01) [C12Q 1/68 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/158 (2013.01); G01N 2800/06 (2013.01); G01N 2800/50 (2013.01); G01N 2800/52 (2013.01); G01N 2800/60 (2013.01)] 3 Claims
 
1. A method for treating eosinophilic gastritis (EG) or eosinophilic gastroenteritis (EGE) in a subject in need thereof, the method comprising
a) determining amounts of CCL26 protein, IL-5 protein, and TSLP protein, or peptide or polypeptide fragments thereof in a serum fraction of a blood sample obtained from the subject at an initial time point;
b) detecting an elevated amount of two or more of CCL26, IL-5, and TSLP proteins, or peptide or polypeptide fragments thereof, in the serum fraction, relative to a predetermined control value;
c) diagnosing the subject as having EG or EGE; and
d) administering to the subject diagnosed with EG or EGE i) a therapeutic agent selected from the group consisting of a glucocorticoid, a leukotriene inhibitor, azathioprine, an anti-histamine, a mast-cell stabilizer, a macrolide antibiotic, and anti-cytokine therapy, or ii) a dietary therapy which alleviates one or more symptoms or complications of EG or EGE selected from a restricted diet, an elemental diet, and an elimination diet.